{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.8","upperLimit":"77.0","value":"52.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Major Cytogenetic Response (MCyR) rate was defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response. The percentage of treated participants in each arm with MCyR is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 2"}],"paramType":"NUMBER","populationDescription":"Secondary efficacy endpoint pre-specified only for participants treated in Cohort 2","reportingStatus":"POSTED","timeFrame":"From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)","title":"Major Cytogenetic Response (MCyR) Rate in Cohort 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}